

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 14A
(RULE 14a-101)**

SCHEDULE 14A INFORMATION

**PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.)**

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

- ☐ Preliminary Proxy Statement
- ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2))
- ☐ Definitive Proxy Statement
- ☒ Definitive Additional Materials
- ☐ Soliciting Material under §240.14a-12

Pelthos Therapeutics Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- ☒ No fee required
 - ☐ Fee paid previously with preliminary materials.
 - ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
-

Your **Vote** Counts!

PELTHOS THERAPEUTICS INC.

2026 Annual Meeting
Vote by September 28, 2026
11:59 PM ET

PELTHOS THERAPEUTICS INC.
4020 STIRRUP CREEK DRIVE, SUITE 110
DURHAM, NC 27703



T02639-P56339

You invested in PELTHOS THERAPEUTICS INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on September 29, 2026.**

Get informed before you vote

View the Notice and Proxy Statement and our Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to September 15, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxymaterial.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and
vote without entering a
control number



Vote Virtually at the Meeting*

September 29, 2026
9:00 a.m. ET

Virtually at:

www.virtualshareholdermeeting.com/PTHS2026

Vote by Mail:

You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the more complete proxy materials that are available to you on the internet. You may view the proxy materials at www.proxyvote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote on these important matters.

Voting Items		Board Recommends
1.	To elect eight (8) members of the Company's Board of Directors (the "Board"), each to serve until the next annual meeting of the Company's shareholders, or until each of their respective successors are elected and qualified or their earlier resignation or removal ("Proposal No. 1"). Nominees: 01) Peter Greenleaf 05) Ezra Friedberg 02) Richard Baxter 06) Dr. Richard Malamut 03) Todd Davis 07) Matthew Pauls 04) Andrew Einhorn 08) Scott Plesha	✔ For
2.	To ratify the Board's selection of Grant Thornton LLP as the Company's independent registered public accountants for the fiscal year ending December 31, 2026 ("Proposal No. 2"); and	✔ For
3.	To approve the Pelthos Therapeutics Inc. 2026 Equity Incentive Plan ("Proposal No. 3").	✔ For
NOTE: In his discretion, the proxy is authorized to vote upon such other business that may properly come before the Annual Meeting.		

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".